To characterize the effects of orally administered probenecid on the phannacokinetics of cefoxitin in healthy male volunteers, we administered to one group of six subjects 2 g of cefoxitin by intravenous (i.v.) bolus either alone, with 1 g of probenecid concomitantly, or when 1 g of probenecid was administered 1 h previously by using a crossover design. Likewise, we administered to a second group of six subjects 2 g of cefoxitin intramuscularly (i.m.) Probenecid competitively inhibits the rena tubular secretion of other organic acids (20) anc has been used with penicillins and cephalospo rins to increase and sustain antibacterial concen trations to enhance therapeutic efficacy (3,8,11) Cefoxitin, a cephamycin derivative, is eliminatec primarily by glomerular filtration and tubulsi secretion (17). The purpose of the present stud) was to characterize the effect of probenecid or the blood and urine concentrations of intrave nously (i.v.) and intramuscularly (i.m.) admin istered cefoxitin. The portion of the study or i.v.-administered cefoxitin allowed a completE pharmacokinetic analysis ofthe effect of proben ecid on the disposition of cefoxitin. The portior on i.m.-administered cefoxitin allowed us to as sess the interaction under the conditions of comr mon clinical use (1).
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(This work was presented in part at the Amer ican Federation for Clinical Research, Easteri Section meetings, Boston, Mass., 19 Octobei
1979.) MATERIALS AND METHODS
Subjects. After the protocol was approved by the Thomas Jefferson University Committee on Research, 12 male volunteers, age 21 to 35 years, gave written informed consent to participate in the study. They 1 were all within ±10% of ideal body weight and judged 1 to be healthy on the basis of a normal physical exam- ination and the results of laboratory screening studies, including serum urea nitrogen and creatinine, and urinalysis.
Design. The volunteers were randomly assigned to two parallel groups. Group I (n = 6) received each of r the following treatments in random sequence: (A) 2 The individual and mean (± SD) incremental and total urinary recoveries of cefoxitin are listed in Table 2 . Beginning with the 2-to 3-h collection period, mean cefoxitin urine concentrations were significantly increased in the probenecidtreated groups. Mean total 24-h urinary excretion of cefoxitin was 83.5% of the actual dose administered in treatment A, 84.2% in treatment B, and 84.2% in treatment C. Table 3 lists individual pharmacokinetic parameters for cefoxitin during the various i.v. treatments. As expected, the mean C1r of cefoxitin was significantly decreased (P < 0.05) by the coadministration of probenecid (231.0 versus 90.9 ml/min, treatments A and C, respectively). The mean incremental Cl as a function of the corresponding mean serum concentration for the three treatments is depicted in Fig. 1 . Although the mean incremental Cl were constant in treatments A and C, following treatment B they were nonconstant and decreased with time in all but one subject. Because the incremental clearances of cefoxitin were nonconstant in treatment B, certain pharmacokinetic parameters could only be calculated for treatments A and C ( Table 3 ).
The AUC" was significantly (P <0.05) increased after treatments B (197.6 ± 22.0 mg h liter-) and C (321.7 ± 74.7) compared to treatment A (136.0 ± 16.7); in addition, the effect of probenecid pretreatment (treatment C) was significantly (P < 0.05) greater than concomitant probenecid (treatment B).
The individual nonrenal clearances (Cl.,,`) of cefoxitin tended to decrease after probenecid, though the overall change was not statistically significant (P > 0.2). The trend in the Clr2 paralleled the decrease in ClrV.
The mean volume of the central compartment (VI) for individuals in treatment C (8.7 ± 1.3 liter) was not significantly different (P = 0.075) from that for treatment A (8.0 ± 2.0 liter). The mean terminal half-life (t1/2) of cefoxitin was significantly longer (P < 0.05) after treatments B and C (1.5 and 1.6 h, respectively) than after treatment A (0.8 h).
i.m. treatments. Individual and mean (±SD)
cefoxitin serum concentrations for treatments D and E are listed in (Table 5) . Nonetheless, the AUC4 after 2 g of cefoxitin was significantly greater (P < 0.05) after 2 g of probenecid than 1 g.'The ti/,,. for the two treatments were similar to each other (1.4 and 1.7 h for treatments D and E, respectively) and comparable to those for treatments B and C, which employed a different panel of subjects. DISCUSSION Cefoxitin is a new parenteral semisynthetic cephamycin antibiotic (2) whose disposition kinetics are adequately described by a two-compartment open model (16) . After i.v. ainistration, cefoxitin is rapidly distributed and has a serum tl/2 of 40 to 60 min; i.m.-administered cefoxitin is rapidly and completely absorbed after doses up to 2 g (17) . Cefoxitin is primarily eliminated unchanged by glomerular filtration and tubular secretion; <1% is excreted in the bile and <2% is transformed to an inactive decarbamoyl metabolite (16) . 3) inhibition of tubular secretion but also to other mechanisms such as decreases in apparent volumes of distribution or Cl. (4, 6, 15) . Because of S the diverse effects of probenecid on drug disposition, a study to characterize the effects of the timing and dose of probenecid on the pharmacokinetics of cefoxitin was undertaken.
In the present study, probenecid increased the serum concentrations and prolonged the elimi- (1 g) in group I (n = 6).
ume of distribution is dependent on the pharmacokinetic model employed (10) . The previous studies primarily report changes in the hybrid pharmacokinetic parameters Vd,8, the pseudoequilibrium volume of distribution, and Vd area, the volume of distribution calculated from the area under the curve. However, as probenecid decreases the overall rate constant of drug elimination (k10) for these compounds, these hybrid volumes are altered numerically within the model but do not reflect an actual change in distributive space. Calculation of the V1 is elimination rate independent and thus a more appropriate measure of actual distribution volume (10) .
Probenecid has been reported to decrease the ClI, of cloxacillin, cinoxacin, and cefazedone (13, 15, 18) due to competition for a common metabolic pathway or an inhibition of biliary clearance. This effect of probenecid would be most evident with drugs that are extensively metabolized. In this study, probenecid tended to decrease the rate of Clnr'24 of cefoxitin, but the effect was not significant; this may be explained by the small degree of metabolism and biliary excretion of cefoxitin (16) .
Administration of 1 and 2 g of probenecid concomitantly with i.m.-administered cefoxitin resulted in a dose-related increase in cefoxitin AUC"4. The cefoxitin AUC 24after the 2-g dose of probenecid was comparable to that obtained when 1 g of probenecid was given 1 h before i.v.-administered cefoxitin. The urinary recoveries of cefoxitin after i.m. treatments were comparable to those after the i.v. treatments with or without probenecid. This demonstrated that i.m. and i.v. administration of cefoxitin have comparable bioavailability and that probenecid delays but does not diminish the renal excretion of cefoxitin.
